AMRN will fold without an expansion of the usage being approved. They know it. They don't have the means to do battle with BP with only one drug in their pipeline and reluctant acceptance of the science in the medical community. Their clip has only 1 bullet in it. The target is over a mile away. They need a bulls-eye. Odds are low in getting it. Moral of the story: your losses will become permanent without an overwhelming show from the Reduce It study many years from today. Of note: I admire the initiative many of the investors have taken to try to change things here. It was impressive and inspiring. But sometimes false hope is worse than no hope at all.
One more thing....don't call me Francis. My father called me Francis, once.
another thing that Francis has forgotten, and to your point about script growth....our major competitor does $900 million a year with an inferior product.....there is an established market for this product that is there for the taking........at some price [yet to be agreed upon], a company with some marketing and sales muscle will play.......when the Amarin Board loses all leverage [getting close], they will deal....IMHO
Market Data 
Markets 
AI
